StreetAlpha.app
Home › Stocks › TENX

Tenax Therapeutics, Inc. (TENX)

Healthcare
$1.25
▼ −10.07%
LAST CLOSE · NOV 20

Tenax Therapeutics develops oral levosimendan, a drug candidate for pulmonary hypertension in heart failure with preserved ejection fraction. It last closed at $1.25 on Nov 20, down 10.07% on the day. The next earnings report for TENX is expected around Tue, Mar 9, 2027. For the quarter ended Sep 2026, TENX reported EPS of -$0.31 on revenue of $0. Over its last 8 reports the stock moved an average of 7.5% the session after earnings. Over the last 12 months TENX insiders bought $6.5M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is TENX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TENX.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$65.8M
EPS (diluted)
−$1.39
Valuation
Market cap
$56.9M
45.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$113.7M
At Sep 30
Shareholder equity
$108.7M
Shares outstanding
45.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From TENX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 9
Estimated date · Time not announced
Reported EPS
-$0.31
Quarter ended Sep 2026
Year ago EPS
-$0.40
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.22Dec '24Mar 2025: -$0.28Mar '25Jun 2025: -$0.27Jun '25Sep 2025: -$0.40Sep '25Dec 2025: -$0.38Dec '25Mar 2026: -$0.35Mar '26Jun 2026: -$0.35Jun '26Sep 2026: -$0.31Sep '26Latest -$0.31
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How TENX moved after its last 8 reports
Average move the session after a report ±7.5%
Nov 5, 2026Time not announced−9.9%
Jul 31, 2026Time not announced−9.3%
May 12, 2026Time not announced+1.8%
Mar 10, 2026Time not announced+31.7%
Nov 12, 2025After the close−4.3%
Aug 13, 2025After the close+0.7%
May 14, 2025After the close+0.3%
Mar 25, 2025After the close−2.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TENXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TENX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TENX

Technical Analysis

TENX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 32% below its 20 day and 39% below its 50 day average. It is 630% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $1.24, and the nearest resistance the Pivot at $1.28.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 10.9%/day
Key levels
$19.4052 week high+1452.0%
$9.12200 day average+629.6%
$5.31100 day average+324.8%
$1.84Swing high (Oct 22)+47.2%
$1.7450 day average+39.2%
$1.6520 day average+32.0%
$1.32Pivot R1+5.6%
$1.28Pivot+2.4%
$1.25Last close
$1.2452 week low−0.8%
$1.21Pivot S1−3.2%
Indicators
RSI (14)28.38Oversold below 30Oversold
MACD-0.14Below its signal lineBearish
Stochastic8.5Near the bottom of its rangeOversold
ADX (14)24.5Weak trend
Williams %R-98.5Oversold below −80, overbought above −20Oversold
CCI (20)-191.8Oversold below −100, overbought above 100Oversold
Rate of change−26.0%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 10.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TENX

What happened before

See how TENX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TENX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TENX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TENXHow many large options trades hit TENX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TENX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●66 buying vs 58 selling
  • ▲Held by funds +3.4 pts
  • ▼Funds holding -7
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding106113−6.2%
In funds' top 1004−100.0%
Held by funds70.2%66.8%+3.4 pts
New / increased30 / 3645 / 39−21.4%
Reduced / sold out21 / 3714 / 13+114.8%
Put/call ratio0.000.05−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TENX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TENX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$6.5M10 buys · 5 insiders
Sold$00 sales · 0 insiders
Cluster buy: 4 insiders bought $4.9M between Aug 20 and Sep 16.
2025-12 bought $96K2026-08 bought $1.8M2026-09 bought $3.1M2026-10 bought $1.5MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 21ADAR1 Capital Management, LLC10% ownerBuy922,849$1.59$1.5M
Sep 16Declan DooganDirectorBuy53,000$1.92$102K
Sep 15Christopher Thomas GiordanoCEOBuy10,850$1.85$20K
Sep 11Thomas R Staab IICFOBuy5,675$1.94$11K
Sep 3ADAR1 Capital Management, LLC10% ownerBuy900,000$1.78$1.6M
Sep 2ADAR1 Capital Management, LLC10% ownerBuy770,333$1.79$1.4M
Every insider buy and sale for TENX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TENX insider trades →

From SEC Form 4 filings by TENX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TENX is in one of them and how their past TENX trades turned out.

TENX in the AI portfolios
Loading…

TENX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TENX in an article yet. Here's the latest on the wider market.

TENX in the news

About Tenax Therapeutics

Tenax Therapeutics is a pharmaceutical company developing drugs for cardiopulmonary conditions. Its main candidate is oral levosimendan, a drug already marketed in other countries for acute heart failure, which it is testing for pulmonary hypertension in heart failure with preserved ejection fraction. No therapy is currently approved for that condition in the United States. The company is based in Chapel Hill, North Carolina, and targets patients with this form of pulmonary hypertension.

Headquarters
Chapel Hill, NC